Abeona Therapeutics Q3 2026 Earnings Date & Estimates

Abeona Therapeutics (NASDAQ:ABEO) is a biotechnology company focused on developing and commercializing cell and gene therapies for serious diseases. The company’s primary focus is regenerative medicine, with an emphasis on treatments that address rare genetic disorders and conditions involving damaged or absent tissue.

Abeona’s lead product, ZEVASKYN (prademagene zamikeracel, formerly EB-101), is an autologous, gene-corrected cell therapy for wounds associated with recessive dystrophic epidermolysis bullosa (RDEB). The treatment uses a patient’s own skin cells, which are genetically modified to produce functional type VII collagen and expanded into replacement skin grafts for chronic wounds.

The U.S. Food and Drug Administration approved ZEVASKYN in 2025 for eligible adult and pediatric patients with RDEB. Abeona is based in the United States and has developed its therapies through U.S. research, manufacturing, and regulatory operations. The company continues to focus on advancing specialized cell and gene therapies for patients with limited treatment options.